Fennec Pharmaceuticals, Inc.

RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 25, 2025 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on June 3, 2025. Detailed results of the vote for the election of directors are set out below: Name of Nominee Votes For % Votes For Votes Withheld % Votes Withheld Dr. Khalid Islam 13,858,131 97.84% 304,760 2.15% Mr. Chris A. Rallis 13,808,792 97.49% 354,099 2.50% Mr. Marco Brughera 13,807,501 97.49% 355,390 2.50% Dr. Jodi Cook 13,259,894 93.62% 902,997 6.37% Mr. Rostislav Raykov 13,432,561 94.84% 730,330 5.15% Mr. Jeff Hackman 13,495,309 95.28% 667,582 4.71% Shareholders voted 99.64% in favor of appointing Haskell & White LLP as auditors and authorizing the directors to fix the auditor remuneration, 85.50% in favor of the compensation paid to the Company’s named executive officers, and 91.27% (88.01% after subtracting shares held by insiders eligible to participate in the Company’s 2020 Equity Incentive Plan) in favor of certain amendment to the Company’s 2020 Equity Incentive Plan. The Company has relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq, in the approval of the amendments to its 2020 Equity Incentive Plan. For further information, please contact: Robert Andrade Chief Financial Officer Fennec Pharmaceuticals Inc. Tel: 919-246-5299 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Norgine has entered into a definitive agreement to acquire Theravia, a pharma laboratory that specialises in rare and debilitating condition treatments. The acquisition is expected to be a primary growth driver for Norgine in the medium to long term. Credit: National Cancer Institute on Unsplash. This transaction is said to be contingent on receiving customary regulatory approvals. Theravia’s portfolio includes Siklos for sickle cell disease and Orphacol for genetic disorders affecting the liver’s bile production. Both products are intended for the adult and paediatric population with these conditions. The products that encompass the therapeutic areas of rare haematology and hepatology are said to align with Norgine’s current portfolio of rare and specialty medicines. With the addition of Theravia’s offerings, Norgine’s rare disease portfolio will now feature six core products: eflornithine, mavorixafor, Pedmarqsi, Agilus, Orphacol, and Siklos. This acquisition is expected to be a primary growth driver for Norgine in the medium to long term. Recent transactions involving Fennec Pharma’s Pedmarqsi and X4 Pharma’s mavorixafor highlight Norgine’s focus on expanding its presence in the rare disease and specialty pharmaceuticals market by means of acquisitions as well as in-licensing. Norgine CEO Janneke van der Kamp said: “This acquisition is a unique opportunity for Norgine to bolster our growth trajectory, as well as our rare disease portfolio. “With our strong legacy and proven track record of successfully bringing innovative treatments to patients, we believe we are well placed to ensure the Theravia medicines reach their full potential.” Theravia was established via the Addmedica and CTRS merger, with an aim to fulfil the medical requirements of individuals suffering from these difficult-to-treat ailments. Theravia CEO Franck Hamalian said: “The joining of our companies brings together the skills, know-how and geographical presence that will create a European-based champion of rare and ultra rare disease. “Our combined product portfolios and Norgine’s legacy and experience will enable broader access to medicines for patients with high unmet medical needs.

Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines. Transaction further establishes Norgine's position as a partner of choice for commercialising rare and specialty pharmaceuticals in Europe. PARIS, April 15, 2025 /PRNewswire/ -- Norgine and Theravia announced today that they have entered into a definitive agreement under which Norgine will acquire Theravia, an international pharmaceutical company specialising in cutting-edge treatments for patients with rare and debilitating conditions. Recent deals with Fennec Pharma for PEDMARQSI® and X4 Pharma for mavorixafor demonstrate Norgine's strong emphasis on driving growth in rare disease and specialty medicines through acquisitions and in-licensing. Theravia's innovations have resulted in successful launches of life-saving medications which have changed patient outcomes worldwide. Theravia has several products in the rare disease space, including SIKLOS®, for adults and children with sickle cell disease, and ORPHACOL®, a medicine for adults and children who have a genetic disorder that affects bile production by the liver. These products span both the rare haematology and rare hepatology therapeutic areas and are complementary to Norgine's existing rare and specialty portfolio. The development of Theravia in the past few years has been supported by its majority shareholder Mérieux Equity Partners, a healthcare dedicated investment firm based in France. said Janneke van der Kamp, Chief Executive Officer, Norgine. Franck Hamalian, Chief Executive Officer, Theravia, added: With the acquisition of Theravia, Norgine will now have six core products in its rare disease portfolio (PEDMARQSI®, eflornithine, mavorixafor, AGILUS®, SIKLOS® and ORPHACOL®) thereby comprising a franchise of critical scale with the ability to be a key growth driver in the medium-to-long-term. Norgine looks forward to building on this transaction as we continue to strengthen our platform for future acquisitions and in-licensing opportunities to drive growth. The transaction remains subject to obtaining customary regulatory approvals from the competent authorities.